,address1,address2,city,state,zip,country,phone,website,industry,sector,longBusinessSummary,companyOfficers,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,lastSplitFactor,lastSplitDate,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,recommendationKey,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,returnOnAssets,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,1275 West Washington Street,Suite 104,Tempe,AZ,85281,United States,602-286-5520,https://www.capstonethx.com,Building Materials,Basic Materials,"Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.","{'maxAge': 1, 'name': 'Mr. Michael M. Toporek', 'age': 56, 'title': 'CEO, Pres & Chairman', 'yearBorn': 1966, 'exercisedValue': 0, 'unexercisedValue': 0}",86400,2,7.5,7.5,7.5,7.5,7.5,7.5,7.5,7.5,0.0,0.181881,2,2,6,0,0,0.232,0.29,10000,10000,1182075,7.5,37.0,7.53,27.3075,0.0,0.0,USD,2820827,0.0,157610,27,33,1308096000,1310688000,0.0007,0.0,0.0089300005,0.35,0.0008,-60.706,1577750400,1609372800,1577750400,-358000,-17.96,1:1000,1568073600,-3.902,PNK,EQUITY,CAPS,CAPS,CAPSTONE THERAPEUTICS CORPORATI,Capstone Therapeutics Corp.,728231400,America/New_York,EDT,-14400000,7.5,none,17000,0.313,-723000,3071000,0.015,0.246,-0.54089,1289125,-1679000,0.0,0.0,0.0,USD,
1,1275 West Washington Street,Suite 104,Tempe,AZ,85281,United States,602-286-5520,https://www.capstonethx.com,Building Materials,Basic Materials,"Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.","{'maxAge': 1, 'name': 'Edward  Schultz', 'title': 'VP,CFO & Treasurer', 'exercisedValue': 0, 'unexercisedValue': 0}",86400,2,7.5,7.5,7.5,7.5,7.5,7.5,7.5,7.5,0.0,0.181881,2,2,6,0,0,0.232,0.29,10000,10000,1182075,7.5,37.0,7.53,27.3075,0.0,0.0,USD,2820827,0.0,157610,27,33,1308096000,1310688000,0.0007,0.0,0.0089300005,0.35,0.0008,-60.706,1577750400,1609372800,1577750400,-358000,-17.96,1:1000,1568073600,-3.902,PNK,EQUITY,CAPS,CAPS,CAPSTONE THERAPEUTICS CORPORATI,Capstone Therapeutics Corp.,728231400,America/New_York,EDT,-14400000,7.5,none,17000,0.313,-723000,3071000,0.015,0.246,-0.54089,1289125,-1679000,0.0,0.0,0.0,USD,
2,1275 West Washington Street,Suite 104,Tempe,AZ,85281,United States,602-286-5520,https://www.capstonethx.com,Building Materials,Basic Materials,"Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.","{'maxAge': 1, 'name': 'Mr. Matthew E. Lipman', 'age': 43, 'title': 'VP, Sec. & Director', 'yearBorn': 1979, 'exercisedValue': 0, 'unexercisedValue': 0}",86400,2,7.5,7.5,7.5,7.5,7.5,7.5,7.5,7.5,0.0,0.181881,2,2,6,0,0,0.232,0.29,10000,10000,1182075,7.5,37.0,7.53,27.3075,0.0,0.0,USD,2820827,0.0,157610,27,33,1308096000,1310688000,0.0007,0.0,0.0089300005,0.35,0.0008,-60.706,1577750400,1609372800,1577750400,-358000,-17.96,1:1000,1568073600,-3.902,PNK,EQUITY,CAPS,CAPS,CAPSTONE THERAPEUTICS CORPORATI,Capstone Therapeutics Corp.,728231400,America/New_York,EDT,-14400000,7.5,none,17000,0.313,-723000,3071000,0.015,0.246,-0.54089,1289125,-1679000,0.0,0.0,0.0,USD,
